PROCEPT BioRobotics announces Aquablation therapy's new Category I CPT code effective January 1, 2026, enhancing access and adoption.
Quiver AI Summary
PROCEPT BioRobotics Corporation announced that its Aquablation therapy has been assigned a Category I Current Procedural Terminology (CPT) code, which will take effect on January 1, 2026. This marks a significant milestone for the company and the urology community, recognizing the clinical value of Aquablation therapy as it aims to become the standard surgical treatment for benign prostatic hyperplasia (BPH). The new CPT code 52XX1, which replaces the previous Category III code, is associated with a proposed payment rate of approximately $540 under Medicare, slightly higher than the payment for traditional TURP procedures. PROCEPT aims to enhance surgeon adoption and patient access to Aquablation therapy, which uses advanced robotic technology to provide precise, heat-free treatment while preserving critical anatomical functions. The company also highlighted its commitment to clinical research, supported by numerous publications on the benefits of Aquablation.
Potential Positives
- Aquablation therapy receiving a Category I CPT code effective January 1, 2026 enhances its recognition and acceptance in the medical community, marking a significant advancement for the company.
- The new CPT code is associated with a higher proposed payment rate of approximately $540, which may encourage surgeon adoption and broaden patient access to the treatment.
- The transition from a Category III to a Category I code highlights the clinical value of Aquablation therapy, further solidifying its position as a potential standard of care for BPH treatment.
- The press release demonstrates PROCEPT's commitment to advancing patient care through innovative urology solutions, supported by extensive clinical evidence with over 150 peer-reviewed publications.
Potential Negatives
- The Proposed Rule regarding payment rates and policies is still subject to change, which introduces uncertainty about future reimbursement for Aquablation therapy.
- The comparison of the proposed payment rate for Aquablation therapy to TURP suggests that it is only marginally higher, potentially limiting its competitive advantage in the market.
- Forward-looking statements in the press release highlight inherent risks and uncertainties, which may concern investors about the company's financial outlook.
FAQ
What is Aquablation therapy?
Aquablation therapy is a robotic-assisted treatment for benign prostatic hyperplasia (BPH) using ultrasound-guided heat-free waterjet technology.
When will the new CPT Category I code for Aquablation take effect?
The new Category I CPT code for Aquablation therapy will take effect on January 1, 2026.
How will the new CPT code affect Aquablation therapy adoption?
The new CPT code is expected to support surgeon adoption and broaden patient access to Aquablation therapy.
What is the proposed Medicare payment for Aquablation therapy in 2026?
The proposed Medicare payment for Aquablation therapy in 2026 is approximately $540, based on 16.14 total RVUs.
What is the significance of the Category I CPT code for Aquablation?
Securing a Category I CPT code marks a major milestone in recognizing the clinical value and widespread use of Aquablation therapy.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$PRCT Insider Trading Activity
$PRCT insiders have traded $PRCT stock on the open market 29 times in the past 6 months. Of those trades, 0 have been purchases and 29 have been sales.
Here’s a breakdown of recent trading of $PRCT stock by insiders over the last 6 months:
- ANTAL ROHIT DESAI has made 0 purchases and 21 sales selling 150,000 shares for an estimated $9,381,353.
- REZA ZADNO (President, CEO) has made 0 purchases and 2 sales selling 21,391 shares for an estimated $1,288,213.
- KEVIN WATERS (EVP, CFO) has made 0 purchases and 2 sales selling 4,395 shares for an estimated $266,342.
- ALALEH NOURI (EVP, CLO, CORP. SEC.) has made 0 purchases and 2 sales selling 3,957 shares for an estimated $241,260.
- HISHAM SHIBLAQ (EVP, Chief Comm. Officer) has made 0 purchases and 2 sales selling 3,835 shares for an estimated $234,074.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$PRCT Hedge Fund Activity
We have seen 144 institutional investors add shares of $PRCT stock to their portfolio, and 141 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PERPETUAL LTD removed 831,739 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $48,457,114
- FRANKLIN RESOURCES INC removed 695,126 shares (-64.8%) from their portfolio in Q1 2025, for an estimated $40,498,040
- WELLINGTON MANAGEMENT GROUP LLP removed 528,717 shares (-35.5%) from their portfolio in Q1 2025, for an estimated $30,803,052
- ARTISAN PARTNERS LIMITED PARTNERSHIP added 513,742 shares (+120.7%) to their portfolio in Q1 2025, for an estimated $29,930,608
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. added 429,461 shares (+43.6%) to their portfolio in Q1 2025, for an estimated $25,020,397
- ALLIANCEBERNSTEIN L.P. added 391,215 shares (+22.3%) to their portfolio in Q1 2025, for an estimated $22,792,185
- PRICE T ROWE ASSOCIATES INC /MD/ added 341,906 shares (+47.9%) to their portfolio in Q1 2025, for an estimated $19,919,443
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$PRCT Analyst Ratings
Wall Street analysts have issued reports on $PRCT in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- B of A Securities issued a "Buy" rating on 04/25/2025
- Truist Securities issued a "Buy" rating on 04/11/2025
- Morgan Stanley issued a "Overweight" rating on 02/26/2025
To track analyst ratings and price targets for $PRCT, check out Quiver Quantitative's $PRCT forecast page.
$PRCT Price Targets
Multiple analysts have issued price targets for $PRCT recently. We have seen 3 analysts offer price targets for $PRCT in the last 6 months, with a median target of $84.0.
Here are some recent targets:
- Craig Bijou from B of A Securities set a target price of $84.0 on 04/25/2025
- Richard Newitter from Truist Securities set a target price of $70.0 on 04/11/2025
- Patrick Wood from Morgan Stanley set a target price of $95.0 on 02/26/2025
Full Release
SAN JOSE, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company dedicated to advancing patient care through transformative urology solutions, today announced that Aquablation therapy was assigned a Category I code effective January 1, 2026.
The 2026 Medicare Proposed Physician Fee Schedule (PFS) includes payment rates for a new Category I Current Procedural Terminology (CPT) code related to Aquablation therapy. Category I CPT code 52XX1 will replace Category III CPT code 0421T as the primary code for Aquablation therapy.
“Securing a Category I CPT Code marks a major milestone for PROCEPT, the urology community, and the patients we serve,” said Sham Shiblaq, chief commercial officer of PROCEPT BioRobotics. “This transition recognizes the clinical value and widespread use of Aquablation therapy as we continue to make progress toward becoming the BPH surgical standard of care. The Category I code will further support surgeon adoption and broaden patient access to a treatment that delivers durable symptom relief with a low risk of sexual side effects.”
The new CPT Category I Code 52XX1 was assigned a 2026 national Medicare physician proposed payment of 16.14 total RVUs which translates to an approximate national average of $540, under the 2026 proposed Medicare PFS. By comparison, TURP was assigned 15.82 total RVUs which translate to an approximate national average of $529.
The PFS Proposed Rule was released on July 14, 2025, and updated payment policies and payment rates for services will be provided for Medicare beneficiaries on or after January 1, 2026. The Proposed Rule release is followed by a public comment period that will close in September 2025 and will culminate in CMS' release of the Final Rule, which is expected to be announced in November 2025 for implementation on January 1, 2026. The Proposed Rule is therefore subject to change.
These 2026 proposed rule payment values and RVU assignments can be viewed on the CMS website at:
https://www.cms.gov/medicare/payment/fee-schedules/physician/federal-regulation-notices/cms-1832-p
About Aquablation Therapy
Aquablation therapy is the first and only ultrasound guided, robotic-assisted, heat-free waterjet for the treatment of BPH. The system’s real-time ultrasound imaging provides the surgeon with a multi-dimensional view of the prostate enabling personalized treatment planning tailored to each patient’s unique anatomy. The surgeon can specify which areas of the prostate to remove while preserving the anatomy that controls erectile function, ejaculatory function and continence. Once the treatment plan is mapped by the surgeon, the predictable robotic-assisted execution enables prostate tissue to be removed in a precise, targeted and controlled fashion.
About PROCEPT BioRobotics Corporation
PROCEPT BioRobotics is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. PROCEPT BioRobotics manufactures the AQUABEAM
®
and HYDROS™ Robotic Systems. The HYDROS Robotic System is the only AI-powered, robotic technology that delivers Aquablation therapy. PROCEPT BioRobotics designed Aquablation therapy to deliver effective, safe, and durable outcomes for males suffering from lower urinary tract symptoms or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. The Company has developed a significant and growing body of clinical evidence with over 150 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy.
Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of federal securities laws. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from those anticipated or implied in such statements. PROCEPT BioRobotics undertakes no obligation to publicly update or revise any forward-looking statements.
Important Safety Information
All surgical treatments have inherent and associated side effects. For a list of potential side effects visit
https://aquablation.com/safety-information/
Investor Contact:
Matt Bacso
VP, Investor Relations and Business Operations
m.bacso@procept-biorobotics.com
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
